WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317580

CAS#: 7261-97-4

Description: Dantrolene sodium is a postsynaptic muscle relaxant that lessens excitation-contraction coupling in muscle cells. It achieves this by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors. It is the primary drug used for the treatment and prevention of malignant hyperthermia, a rare, life-threatening disorder triggered by general anesthesia. It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (e.g. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis), and 2,4-dinitrophenol poisoning.

Price and Availability


USD 265

USD 485

USD 650

Dantrolene, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317580
Name: Dantrolene
CAS#: 7261-97-4
Chemical Formula: C14H10N4O5
Exact Mass: 314.06512
Molecular Weight: 314.253
Elemental Analysis: C, 53.51; H, 3.21; N, 17.83; O, 25.46

Synonym: Dantrolene; Dantroleno; Dantrolenum; Dantrium; Dantrolenum

IUPAC/Chemical Name: 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolinedione


InChi Code: InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+

SMILES Code: C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Nakamura K, Yoshizaki A, Saigusa R, Taniguchi T, Asano Y, Sato S. The efficacy of dantrolene sodium for muscle cramps in patients with localized scleroderma. J Eur Acad Dermatol Venereol. 2015 Nov 11. doi: 10.1111/jdv.13497. [Epub ahead of print] PubMed PMID: 26559172.

2: Qiu YW, Chen D, Xu MY, Li ST. Beneficial effects of dantrolene on sepsis-induced diaphragmatic dysfunction are associated with downregulation of high-mobility group box 1 and calpain-caspase-3 proteolytic pathway. J Surg Res. 2016 Feb;200(2):637-47. doi: 10.1016/j.jss.2015.09.026. Epub 2015 Oct 23. PubMed PMID: 26507277.

3: Xu SY, Hu FY, Ren LJ, Chen L, Zhou ZQ, Zhang XJ, Li WP. Dantrolene enhances the protective effect of hypothermia on cerebral cortex neurons. Neural Regen Res. 2015 Aug;10(8):1279-85. doi: 10.4103/1673-5374.162761. PubMed PMID: 26487856; PubMed Central PMCID: PMC4590241.

4: Plank C, Hofmann P, Gruber M, Bollwein G, Graf BM, Zink W, Metterlein T. Modification of Bupivacaine-Induced Myotoxicity with Dantrolene and Caffeine In Vitro. Anesth Analg. 2015 Sep 29. [Epub ahead of print] PubMed PMID: 26421809.

5: Bulchandani S, Toozs-Hobson P, Kennedy A, Sturman S. Dantrolene an unusual option for detrusor overactivity: observations of a patient with cerebral palsy. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:255-6. doi: 10.1016/j.ejogrb.2015.08.012. Epub 2015 Sep 1. PubMed PMID: 26365833.

6: Penttinen K, Swan H, Vanninen S, Paavola J, Lahtinen AM, Kontula K, Aalto-Setälä K. Correction: Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. PLoS One. 2015 Jul 31;10(7):e0134746. doi: 10.1371/journal.pone.0134746. eCollection 2015. PubMed PMID: 26230682; PubMed Central PMCID: PMC4521935.

7: Ryanodex--a new dantrolene formulation for malignant hyperthermia. Med Lett Drugs Ther. 2015 Jul 6;57(1472):100. PubMed PMID: 26147894.

8: Penttinen K, Swan H, Vanninen S, Paavola J, Lahtinen AM, Kontula K, Aalto-Setälä K. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. PLoS One. 2015 May 8;10(5):e0125366. doi: 10.1371/journal.pone.0125366. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0134746. PubMed PMID: 25955245; PubMed Central PMCID: PMC4425399.

9: Oo YW, Gomez-Hurtado N, Walweel K, van Helden DF, Imtiaz MS, Knollmann BC, Laver DR. Essential Role of Calmodulin in RyR Inhibition by Dantrolene. Mol Pharmacol. 2015 Jul;88(1):57-63. doi: 10.1124/mol.115.097691. Epub 2015 Apr 28. PubMed PMID: 25920678; PubMed Central PMCID: PMC4468648.

10: McKenzie EC, Di Concetto S, Payton ME, Mandsager RE, Arko M. Effect of dantrolene premedication on various cardiovascular and biochemical variables and the recovery in healthy isoflurane-anesthetized horses. Am J Vet Res. 2015 Apr;76(4):293-301. doi: 10.2460/ajvr.76.4.293. PubMed PMID: 25815570.